logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10435369 B1

PDFFull Text
Date of Patent:
Oct. 08, 2019

Filed:

Nov. 08, 2017

Tricyclic sulfones as ror gamma modulators

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

David Marcoux, Pennington, NJ (US);

Myra Beaudoin Bertrand, Lambertville, NJ (US);

T. G. Murali Dhar, Newtown, PA (US);

Michael G. Yang, Narbeth, PA (US);

Zili Xiao, East Windsor, NJ (US);

Hai-Yun Xiao, Belle Mead, NJ (US);

Yeheng Zhu, Stockton, NJ (US);

Carolyn A. Weigelt, Langhorne, PA (US);

Douglas G. Batt, Wilmington, DE (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:

Elliott Korsen

Primary Examiner:

Matthew P Coughlin

Assistant Examiner:

Sagar Patel

Int. Cl.
CPC ...
C07C 317/12 (2006.01); C07C 317/44 (2006.01); A61K 31/10 (2006.01); C07D 211/48 (2006.01); A61P 37/00 (2006.01); C07D 205/04 (2006.01); C07D 205/08 (2006.01); C07D 207/10 (2006.01); C07D 207/16 (2006.01); C07D 207/277 (2006.01); C07D 211/96 (2006.01); C07D 213/40 (2006.01); C07D 213/75 (2006.01); C07D 231/08 (2006.01); C07D 241/08 (2006.01); C07D 257/04 (2006.01); C07D 295/195 (2006.01); C07D 307/22 (2006.01); C07D 309/10 (2006.01); C07D 333/48 (2006.01); C07D 335/02 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 213/81 (2006.01); C07D 215/36 (2006.01); C07D 231/06 (2006.01); C07D 231/18 (2006.01); C07D 233/64 (2006.01); C07D 233/76 (2006.01); C07D 233/78 (2006.01); C07D 233/90 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/04 (2006.01); C07C 317/20 (2006.01); C07C 317/24 (2006.01); C07C 317/30 (2006.01); C07D 405/12 (2006.01); C07D 249/12 (2006.01); C07D 261/18 (2006.01); C07D 263/20 (2006.01); C07D 207/09 (2006.01); C07D 207/28 (2006.01); C07D 285/06 (2006.01); C07D 211/62 (2006.01); C07D 295/16 (2006.01); C07D 211/78 (2006.01); C07D 213/56 (2006.01); C07D 305/08 (2006.01); C07F 9/09 (2006.01);
U.S. Cl.
CPC ...
C07D 211/48 (2013.01); A61P 37/00 (2018.01); C07C 317/20 (2013.01); C07C 317/24 (2013.01); C07C 317/30 (2013.01); C07C 317/44 (2013.01); C07D 205/04 (2013.01); C07D 205/08 (2013.01); C07D 207/09 (2013.01); C07D 207/10 (2013.01); C07D 207/16 (2013.01); C07D 207/277 (2013.01); C07D 207/28 (2013.01); C07D 211/62 (2013.01); C07D 211/78 (2013.01); C07D 211/96 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 213/75 (2013.01); C07D 213/81 (2013.01); C07D 215/36 (2013.01); C07D 231/06 (2013.01); C07D 231/08 (2013.01); C07D 231/18 (2013.01); C07D 233/64 (2013.01); C07D 233/76 (2013.01); C07D 233/78 (2013.01); C07D 233/90 (2013.01); C07D 241/08 (2013.01); C07D 249/12 (2013.01); C07D 257/04 (2013.01); C07D 261/18 (2013.01); C07D 263/20 (2013.01); C07D 285/06 (2013.01); C07D 295/16 (2013.01); C07D 295/195 (2013.01); C07D 305/08 (2013.01); C07D 307/22 (2013.01); C07D 309/10 (2013.01); C07D 333/48 (2013.01); C07D 335/02 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07F 9/091 (2013.01); C07B 2200/05 (2013.01); C07B 2200/07 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2602/38 (2017.05); C07C 2602/44 (2017.05); C07C 2602/50 (2017.05); C07C 2603/08 (2017.05); C07C 2603/12 (2017.05); C07C 2603/16 (2017.05); C07C 2603/90 (2017.05);
Abstract

There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

Find Patent Forward Citations

Loading…